OXIDATIVE STRESS AS A CAUSE OF PARKINSONS-DISEASE

被引:173
作者
JENNER, P
机构
[1] Parkinson's Disease Society Experimental Research Laboratories, King's College London, London
[2] Pharmacology Group, Biomedical Sciences Division, King's College London, London, SW3 6LX, Manresa Road
来源
ACTA NEUROLOGICA SCANDINAVICA | 1991年 / 84卷
关键词
PARKINSONS DISEASE; MPTP; IRON LEVELS; MITOCHONDRIAL FUNCTION; OXIDATIVE STRESS;
D O I
10.1111/j.1600-0404.1991.tb05013.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The cause of dopamine cell death in Parkinson's disease remains unknown. Present interest centres on the possible involvement of a toxin mediated mechanism such as that produced, by MPTP. In post-mortem studies there is evidence in the substantia nigra for an on-going toxic process involving increased lipid peroxidation, altered iron metabolism and impairment of mitochondrial function at the level of complex I. Although the precise relationship between these biochemical changes is not known, present evidence points to oxidative stress as an important factor contributing to neuronal loss. Altered mitochondrial function and increased iron levels may not initiate Parkinson's disease but rather act to accelerate cell death. Future strategies for the treatment of Parkinson's disease should be aimed at preventing oxidative stress and stopping or slowing the progression of the underlying pathology.
引用
收藏
页码:6 / 15
页数:10
相关论文
共 91 条
[1]   INDUCTION BY 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE OF LIPID-PEROXIDATION INVIVO IN VITAMIN-E DEFICIENT MICE [J].
ADAMS, JD ;
ODUNZE, IN ;
SEVANIAN, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 39 (01) :R5-R8
[2]   BIOCHEMICAL-MECHANISMS OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE TOXICITY - COULD OXIDATIVE STRESS BE INVOLVED IN THE BRAIN [J].
ADAMS, JD ;
ODUNZE, IN .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (08) :1099-1105
[3]   BRAIN PEROXIDASE AND CATALASE IN PARKINSON DISEASE [J].
AMBANI, LM ;
VANWOERT, MH ;
MURPHY, S .
ARCHIVES OF NEUROLOGY, 1975, 32 (02) :114-118
[4]   MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE [J].
BINDOFF, LA ;
BIRCHMACHIN, M ;
CARTLIDGE, NEF ;
PARKER, WD ;
TURNBULL, DM .
LANCET, 1989, 2 (8653) :49-49
[5]   INCREASED LIFE EXPECTANCY RESULTING FROM ADDITION OF L-DEPRENYL TO MADOPAR TREATMENT IN PARKINSONS-DISEASE - A LONGTERM STUDY [J].
BIRKMAYER, W ;
KNOLL, J ;
RIEDERER, P ;
YOUDIM, MBH ;
HARS, V ;
MARTON, J .
JOURNAL OF NEURAL TRANSMISSION, 1985, 64 (02) :113-127
[6]  
Birkmayer W, 1983, Mod Probl Pharmacopsychiatry, V19, P170
[7]  
BURNS RS, 1983, P NATL ACAD SCI US, V80
[8]   POTENTIAL BIOACTIVATION PATHWAYS FOR THE NEUROTOXIN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) [J].
CASTAGNOLI, N ;
CHIBA, K ;
TREVOR, AJ .
LIFE SCIENCES, 1985, 36 (03) :225-230
[9]   METABOLISM OF THE NEUROTOXIC TERTIARY AMINE, MPTP, BY BRAIN MONOAMINE-OXIDASE [J].
CHIBA, K ;
TREVOR, A ;
CASTAGNOLI, N .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (02) :574-578
[10]   PARGYLINE AND DEPRENYL PREVENT THE NEUROTOXICITY OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) IN MONKEYS [J].
COHEN, G ;
PASIK, P ;
COHEN, B ;
LEIST, A ;
MYTILINEOU, C ;
YAHR, MD .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 106 (01) :209-210